The PE Ratio as of September 2024 (TTM) for Cassava Sciences, Inc. (SAVA) is -9.51

According to Cassava Sciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.51. This represents a change of -385.35% compared to the average of 3.33 of the last 4 quarters.

Cassava Sciences, Inc. (SAVA) Historical PE Ratio (quarterly & annually)

How has SAVA PE Ratio performed in the past?

The mean historical PE Ratio of Cassava Sciences, Inc. over the last ten years is -15.04. The current -9.51 PE Ratio has changed 6.22% with respect to the historical average. Over the past ten years (40 quarters), SAVA's PE Ratio was at its highest in in the June 2024 quarter at 22.78. The PE Ratio was at its lowest in in the June 2021 quarter at -166.52.

Cassava Sciences, Inc. (SAVA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cassava Sciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cassava Sciences, Inc. (SAVA) Average PE Ratio

How has SAVA PE Ratio performed in the past?

The current PE Ratio of Cassava Sciences, Inc. (SAVA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cassava Sciences, Inc. (SAVA) PE Ratio vs. Peers

How is SAVA’s PE Ratio compared to its peers?

Cassava Sciences, Inc.’s PE Ratio is less than Annovis Bio, Inc. (-2.07), greater than Axsome Therapeutics, Inc. (-14.37), less than Reviva Pharmaceuticals Holdings, Inc. (-1.10), less than Seres Therapeutics, Inc. (-0.89), greater than Anavex Life Sciences Corp. (-10.48), less than INmune Bio, Inc. (-3.01), less than BioVie Inc. (-3.07), less than Cognition Therapeutics, Inc. (-0.73), less than CureVac N.V. (-2.00), greater than Reata Pharmaceuticals, Inc. (-89.36), less than Krystal Biotech, Inc. (49.72), less than Vir Biotechnology, Inc. (-2.19), less than Propanc Biopharma, Inc. (-0.01), less than Exelixis, Inc. (20.78), less than TG Therapeutics, Inc. (33.32), greater than Viking Therapeutics, Inc. (-61.76), greater than Madrigal Pharmaceuticals, Inc. (-10.23), less than BioXcel Therapeutics, Inc. (-0.20),

Build a custom stock screener for Cassava Sciences, Inc. (SAVA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cassava Sciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cassava Sciences, Inc. (SAVA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cassava Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.